Search
Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB22672ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalIt has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Diaziquone
go.drugbank.com/drugs/DB17174ExperimentalCategories: Compounds used in a research, industrial, or household settingPhosphocysteamine
go.drugbank.com/drugs/DB17640ExperimentalCategories: Compounds used in a research, industrial, or household settingALT-2074
go.drugbank.com/drugs/DB05631InvestigationalAn organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Dextromoramide
go.drugbank.com/drugs/DB01529ExperimentalIllicitAn opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalIn pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].
TA-NIC
go.drugbank.com/drugs/DB05445InvestigationalTA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. … It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive
3-Acetylpyridine Adenine Dinucleotide
go.drugbank.com/drugs/DB03363ExperimentalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)